Anti-hepatitis b virus gene medicament based on siRNA pool interference and mediated by complex carrier

A composite vector, viral gene technology, used in antiviral agents, DNA/RNA fragments, gene therapy, etc.

CN101322847AInactive Publication Date: 2008-12-17淮安市第四人民医院
0 Cites 11 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2008-12-17
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a siRNA interference-based anti-HBV gene-based drug mediated by complex carriers. Based on the characteristic of HBV and expression products thereof, active epitope protein in HBsAg expressed by HBV is biologically linked with cationic liposome and specially binds with hepatic cell surface receptors with the help of the epitope protein in the HBsAg to induce RNAi to enter hepatic cells; meanwhile, the meltability of bilayers of the cationic liposome and the cytolipin is used for increasing the efficiency of an siRNA expressed carrier entering into the hepatic cells. The drug of the invention can improve the effectiveness of the siRNA, biological stability in the human body, safety and effective targeting delivery and can be used in the clinical treatment.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to a kind of RNAi anti-hepatitis B virus drug, that is, the effective epitope protein in the hepatitis B surface antigen expressed by hepatitis B virus is biologically linked with cationic liposome to mediate RNAi into the liver cell. The invention specifically relates to a drug based on siRNA Composite carrier-mediated anti-HBV gene drug for pool interference. Background technique

[0002] Persistent infection with hepatitis B virus (HBV) is an important health problem worldwide. There are currently about 350 million infected people in the world, 75% of which are located in the Asia-Pacific region. The 1992-1995 national viral hepatitis serum epidemiological survey showed that the infection rate of hepatitis B virus among Chinese population was 57.6%, and the carrier rate of hepatitis B virus was 9.75%. Based on this, it is estimated that 690 million people in the country have ever been infected with hepatitis B virus, o...

Examples

Embodiment Construction

[0042] Below in conjunction with specific examples, further elaborate the present invention in detail, the prominent substantive features and positive effects of the present invention can be manifested from the following examples, but they do not limit the present invention in any way.

[0043] Material

[0044] psiSTRIKE TM The plasmid kit was purchased from Promega Company, the antibiotic G418 was purchased from Sigma-Aldrich Company, bovine albumin serum (BSA) (component V, purity>98%) was purchased from USB Company, DMEM (Dulbecco's modified eagle's medium), penicillin G ( 5000 units / ml), Trypsin-EDTA, Trizol, DNase I, HBsAg epitope protein-cationic liposome composite carrier was synthesized by ABI company, PureLink TM Viral RNA / DNA kit, mouse monoclonal anti-HBsAg and Alexa Fluor 488 goat anti-mouse IgG were purchased from Invitrogen, and restriction enzymes (PstI, EcoRI, ClaI, BsrGI, SgfI and BglII.) were purchased from New England Biolabs Company, reverse transcriptas...